SatoMHanQMizutaKMoriRKangBMMorinagaSet al
The Wegovy label covers cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, long-term weight reduction in adults and in pediatric patients aged 12 and older with obesity and in adults with overweight plus at least one weight-related comorbid condition, and noncirrhotic MASH with moderate to advanced fibrosis under accelerated approval
Edden RA, Puts NA, Harris AD, Barker PB, Evans CJ
Abnousian A, Vasquez J, Sasaninia K, Kelley M, Venketaraman V
Researchers developed it starting in the 1990s at Monash University with the specific goal of separating hGHs lipolytic function from its growth-promoting and insulin-desensitizing effects, producing a compound studied almost exclusively in the context of fat metabolism rather than general growth hormone replacement
June 2023 Updates: Highmark distributed the July 2023 Plan for Health Newsletter: May 2023 Updates: Highmark to host an educational webinar about My Highmark, the digital experience for members: Webinar to cover how clients can leverage rewards via My Highmark
